RDI cell therapy loan · Biotech

Eyestem secures ₹125 crore RDI debt financing for cell therapies

An initial ₹50 crore disbursement supports the Bengaluru company’s regenerative medicine programme.

Eyestem Research secured ₹125 crore in debt financing through India’s Research, Development and Innovation programme, administered by the Technology Development Board. The agreement was part of the first RDI signing ceremony on May 13, 2026.

The government confirmed an initial ₹50 crore electronic transfer to Eyestem. That payment is a tranche of the approved financing, rather than an additional round. TDB’s project compendium identifies the full ₹125 crore support as debt against a ₹250 crore project.

The funding supports cell therapies for geographic atrophy linked to age-related macular degeneration and idiopathic pulmonary fibrosis. Eyestem develops scalable cell replacement treatments and is evaluating its lead retinal therapy, Eyecyte-RPE, in clinical studies.

Use of funds

Develop and commercialise cell therapies for geographic atrophy and pulmonary fibrosis

Funding history

RDI cell therapy loan · This round₹1.3B

Sources

  1. TDB RDI scheme compendium: approved project instrument and amounttdb.gov.in
  2. Government confirms five signed RDI agreements and first disbursementpib.gov.in · May 16, 2026